The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 percent of their total body weight over the 72-week trial. SUBSCRIBE LOG IN ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Endocrinology > Obesity Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says — Dual GLP-1/GIP drug yielded an average 47% greater relative weight loss compared to ...

The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.

Diabetes drug Mounjaro helped people lose 16% of weight, study finds Two trials have now found tirzepatide, sold under the brand name Mounjaro as a diabetes treatment, to be effective for weight loss.

Diabetes drug promotes weight loss. Tirzepatide is part of a new class of drugs called called GLP-1 ... controlled clinical trial demonstrated that tirzepatide led to a 20 percent reduction ...

Eli Lilly's tirzepatide helped people lose up to 50 pounds, the sort of weight loss results only consistently seen with bariatric surgery. ... The trial was run in the U.S., Argentina, Brazil, ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Lilly’s Zepbound ® (tirzepatide) superior to Wegovy ® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs 13.7%. News release. Eli Lilly and Company.